OneOncology, a national partnership of community oncology practices, says that its partner practices have begun treating patients with 2 anticancer biosimilars: Kanjinti, a trastuzumab biosimilar referencing Herceptin, and Mvasi, a bevacizumab biosimilar referencing Avastin.
OneOncology, a national partnership of community oncology practices, says that its partner practices have begun treating patients with 2 anticancer biosimilars: Kanjinti, a trastuzumab biosimilar referencing Herceptin, and Mvasi, a bevacizumab biosimilar referencing Avastin.
The products, both made by Amgen, were launched in the United States just last month at list prices that represent 15% discounts off the list prices of their respective reference products, though these list prices do not reflect discounts and rebates.
OneOncology says that it has adopted both of the biosimilars as preferred formulary agents as part of its cost-effectiveness strategy.
Jeffrey Patton, MD, OneOncology’s president of physician services, said in a statement that “Making Mvasi and Kanjinti preferred OneOncology agents gives our physicians immediate access to cutting-edge therapies and reinforces our commitment to leading the oncology marketplace and delivering the highest-quality and most cost-effective care to our patients."
Lee Schwartzberg, MD, chief medical officer of OneOncology, added that, "As we begin to incorporate biosimilar medications into our treatment pathways, we will collaborate with our physicians to navigate the fluctuating healthcare landscape and drive initiatives that ensure our clinicians appropriately utilize the right therapeutic sequence at the right time for the right patient."
News that the group has begun to use biosimilars so shortly after their launch comes as welcome news to biosimilar stakeholders; while anticancer biosimilars, including trastuzumab, are already available and widely used in Europe, concerns have persisted that US clinicians might not be swift to adopt biosimilars. In part, those concerns have been related to historically sluggish biosimilar uptake for products in the rheumatology space, but concerns have also surrounded barriers such as provider mistrust and lack of awareness in the oncology setting.
To help remedy those issues, groups like the American Society of Clinical Oncology have stepped up their educational efforts, including issuing a 2018 statement that offered clinicians guidance on using biosimilars in oncology.
In the European context, the European Society of Medical Oncology has also provided extensive educational materials for clinicians, including a 2018 paper that focuses on the integration of biosimilars into routine oncology practice.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.